Helen Tayton-Martin
Tayton-Martin, the firm’s current chief operating officer, will bjoin the board as executive director along with Jonathan Knowles, who will become non-executive director.
With the new appointments the T cell therapy company hopes to strengthen its leadership to support the opening of three pilot cancer trials and an HIV trial earlier this year.